Literature DB >> 14566470

[Drug treatment of sleep disorders in the elderly].

M H Wiegand1.   

Abstract

Changes in the pattern of sleep, e.g. more frequent nocturnal awakenings, are normal in the elderly. There is also a greater incidence of medical and psychiatric sleep disorders (depression, dementia). Initially, a thorough diagnostic assessment should be performed in order to identify disorders which can be treated specifically. For the symptomatic drug treatment of insomnias, the specific metabolic and pharmacokinetic, as well as possible interactions, should be considered. The new benzodiazepine receptor agonists (zopiclone, zolpidem and zaleplone), with their favourable risk-benefit profile, can be considered as first-choice treatments in elderly patients; in general, they should be preferred to the classical benzodiazepines. When a longer treatment is necessary, certain (non-anticholinergic) antidepressants and neuroleptics can be considered (the latter especially in cases of abnormal nocturnal behaviour). Herbal drugs and other hypnotically active compounds play a secondary role. Drug treatment of insomnia should always be carried out in the context of a general treatment plan which also includes non-pharmacological elements. In elderly patients, "chronotherapeutic" methods, which accentuate the sleep-wake rhythm, are of crucial importance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14566470     DOI: 10.1007/s00108-003-1030-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  2 in total

Review 1.  Insomnia in the elderly: a review for the primary care practitioner.

Authors:  S Ancoli-Israel
Journal:  Sleep       Date:  2000-02-01       Impact factor: 5.849

Review 2.  [Recommendations for the diagnosis and therapy of insomnia. German Society of Sleep Research and Sleep Medicine DGSM].

Authors:  P Clarenbach; R Steinberg; H G Weess; M Berger
Journal:  Nervenarzt       Date:  1995-10       Impact factor: 1.214

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.